Current state in the development of candidate therapeutic HPV vaccines

Expert Review of Vaccines

Volumn 15, Issue 8, 2016, Pages 989-1007

  Yang, Andrew ^a   Jeang, Jessica ^a   Cheng, Kevin ^a   Cheng, Ting ^a   Yang, Benjamin ^a   Wu, T C ^a,b   Hung, Chien Fu ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Adjuvant; Cervical cancer; Clinical trials; Combinatorial approach; HPV; HPV E6; HPV E7; Human papillomavirus; Immunotherapy; Therapeutic vaccines

Indexed keywords

BACTERIAL VECTOR; DENDRITIC CELL VACCINE; DNA VACCINE; IMMUNOMODULATING AGENT; IMMUNOSTIMULATING AGENT; NUCLEIC ACID; PEPTIDE; PROTEIN; RNA VACCINE; TUMOR CELL VACCINE; VIRUS VECTOR; WART VIRUS VACCINE;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; THERAPY EFFECT; VACCINATION; WHOLE CELL; DRUG DEVELOPMENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; PAPILLOMAVIRUS INFECTIONS; TRENDS;

DRUG DISCOVERY; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 84961211668     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2016.1157477     Document Type: Article

References (149)

1. K.Wakeham, K.Kavanagh The burden of HPV-associated anogenital cancers. Curr Oncol Rep. 2014;16(9):402.
2. D.Forman, C.de Martel, C.J.Lacey. et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12–23.
3. J.H.Maxwell, J.R.Grandis, R.L.Ferris. HPV-associated head and neck cancer: unique features of epidemiology and clinical management. Annu Rev Med. 2015;67:91–101.
4. H.Mehanna, T.Beech, T.Nicholson, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer–systematic review and meta-analysis of trends by time and region. Head Neck. 2013;35(5):747–755.
5. D.M.Harper. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines. 2009;8(12):1663–1679.
6. N.Kash, M.A.Lee, R.Kollipara, et al. Safety and efficacy data on vaccines and immunization to human papillomavirus. J Clin Med. 2015;4(4):614–633.
7. D.M.Harper, K.B.Williams. Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Discov Med. 2010;10(50):7–17.
8. B.Ma, B.Maraj, N.P.Tran, et al. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs. 2012;17(4):469–492.
9. A.G.Ostor. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12(2):186–192.
10. R.Ghittoni, R.Accardi, S.Chiocca, et al. The role of human papillomaviruses in carcinogenesis. Ecancermedicalscience. 2015;9:526.
11. R.Klaes, S.M.Woerner, R.Ridder, et al. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res. 1999;59(24):6132–6136.
12. H.zur Hausen. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342–350.
13. J.Doorbar. Model systems of human papillomavirus-associated disease. J Pathol. 2016;238(2):166–179.
14. H.Arias-Pulido, C.L.Peyton, N.E.Joste, et al. Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. J Clin Microbiol. 2006;44(5):1755–1762.
15. M.Pett, N.Coleman. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol. 2007;212(4):356–367.
16. E.Gray, M.R.Pett, D.Ward, et al. In vitro progression of human papillomavirus 16 episome-associated cervical neoplasia displays fundamental similarities to integrant-associated carcinogenesis. Cancer Res. 2010;70(10):4081–4091.
17. Y.Yao, W.Huang, X.Yang, et al. HPV-16 E6 and E7 protein T cell epitopes prediction analysis based on distributions of HLA-A loci across populations: an in silico approach. Vaccine. 2013;31(18):2289–2294.
18. M.C.Feltkamp, H.L.Smits, M.P.Vierboom, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 1993;23(9):2242–2249.
19. A.B.Riemer, D.B.Keskin, G.Zhang, et al. A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers. J Biol Chem. 2010;285(38):29608–29622.
20. A.Kumar, S.Hussain, I.S.Yadav, et al. Identification of human papillomavirus-16 E6 variation in cervical cancer and their impact on T and B cell epitopes. J Virol Methods. 2015;218:51–58.
21. A.Mahdavi, B.J.Monk. Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologist. 2005;10(7):528–538.
22. A.-S.Bergot, A.Kassianos, I.H.Frazer, et al. New approaches to immunotherapy for HPV associated cancers. Cancers (Basel). 2011;3(3):3461–3495.
23. D.A.Sewell, Z.K.Pan, Y.Paterson. Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine. 2008;26(41):5315–5320.
24. L.G.Bermudez-Humaran, N.G.Cortes-Perez, Y.Le Loir, et al. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol. 2004;53(Pt 5):427–433.
25. N.G.Cortes-Perez, V.Azevedo, J.M.Alcocer-Gonzalez, et al. Cell-surface display of E7 antigen from human papillomavirus type-16 in Lactococcus lactis and in Lactobacillus plantarum using a new cell-wall anchor from lactobacilli. J Drug Target. 2005;13(2):89–98.
26. K.Adachi, K.Kawana, T.Yokoyama, et al. Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7. Vaccine. 2010;28(16):2810–2817.
27. P.Schnupf, D.A.Portnoy. Listeriolysin O: a phagosome-specific lysin. Institut Pasteur [Microbes Infect]. 2007;9(10):1176–1187.
28. C.Peters, Y.Paterson. Enhancing the immunogenicity of bioengineered Listeria monocytogenes by passaging through live animal hosts. Vaccine. 2003;21(11–12):1187–1194.
29. Z.Chen, L.Ozbun, N.Chong, et al. Episomal expression of truncated listeriolysin O in LmddA-LLO-E7 vaccine enhances antitumor efficacy by preferentially inducing expansions of CD4+FoxP3- and CD8+ T cells. Cancer Immunol Res. 2014;2(9):911–922.
30. A.Darji, C.A.Guzman, B.Gerstel, et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell. 1997;91(6):765–775.
31. M.R.Krul, E.J.Tijhaar, J.A.Kleijne, et al. Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strains. Cancer Immunol Immunothe CII. 1996;43(1):44–48.
32. J.G.Gomez-Gutierrez, K.G.Elpek, R.Montes de Oca-Luna, et al. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother CII. 2007;56(7):997–1007.
33. D.W.Liu, Y.P.Tsao, J.T.Kung, et al. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol. 2000;74(6):2888–2894.
34. M.C.Cassetti, S.P.McElhiney, V.Shahabi, et al. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine. 2004;22(3–4):520–527.
35. C.-J.Hsieh, T.W.Kim, C.-F.Hung, et al. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine. 2004;22(29–30):3993–4001.
36. L.K.Borysiewicz, A.Fiander, M.Nimako, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 1996;347(9014):1523–1527.
37. A.Lamikanra, Z.K.Pan, S.N.Isaacs, et al. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site. J Virol. 2001;75(20):9654–9664.
38. K.Zurkova, K.Babiarova, P.Hainz, et al. The expression of the soluble isoform of hFlt3 ligand by recombinant vaccinia virus enhances immunogenicity of the vector. Oncol Rep. 2009;21(5):1335–1343.
39. A.Baez-Astua, E.Herraez-Hernandez, N.Garbi, et al. Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses. J Virol. 2005;79(20):12807–12817.
40. M.Walczak, J.Regts, A.J.van Oosterhout, et al. Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system. Antivir Ther. 2011;16(2):207–218.
41. A.Riezebos-Brilman, J.Regts, E.-J.Freyschmidt, et al. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Gene Ther. 2005;12(18):1410–1414.
42. A.Riezebos-Brilman, J.Regts, M.Chen, et al. Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12. Vaccine. 2009;27(5):701–707.
43. P.P.Ip, A.Boerma, M.Walczak, et al. Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines. Gene Ther. 2015;22(7):560–567.
44. F.Grasso, D.R.Negri, S.Mochi, et al. Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein. Journal International du Cancer [Int J Cancer]. 2013;132(2):335–344.
45. C.-L.Chang, B.Ma, X.Pang, et al. Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer. Mol Ther J Am Soc Gene Ther. 2009;17(8):1365–1372.
46. L.Ginaldi, M.F.Loreto, M.P.Corsi, et al. Immunosenescence and infectious diseases. Institut Pasteur [Microbes Infect]. 2001;3(10):851–857.
47. K.Lin, K.Doolan, C.-F.Hung, et al. Perspectives for preventive and therapeutic HPV vaccines. J Formosan Med Assoc = Taiwan Yi Zhi. 2010;109(1):4–24.
48. R.Rosales, C.Rosales. Immune therapy for human papillomaviruses-related cancers. World J Clin Oncol. 2014;5(5):1002–1019.• A comprehensive review for various preventative and therapeutic strategies against HPV-associated diseases.
49. J.-H.Su, A.Wu, E.Scotney, et al. Immunotherapy for cervical cancer: research status and clinical potential. Biodrugs Clin Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 2010;24(2):109–129.
50. C.-F.Hung, B.Ma, A.Monie, et al. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther. 2008;8(4):421–439.
51. J.W.Kim, C.F.Hung, J.Juang, et al. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther. 1011-1018;11(12):2004.
52. T.M.Fu, J.B.Ulmer, M.J.Caulfield, et al. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med. 1997;3(6):362–371.
53. A.Porgador, K.R.Irvine, A.Iwasaki, et al. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med. 1998;188(6):1075–1082.
54. M.A.Chattergoon, T.M.Robinson, J.D.Boyer, et al. Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells. J Immunol. 1998;160(12):5707–5718.
55. M.Dupuis, K.Denis-Mize, C.Woo, et al. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol. 2000;165(5):2850–2858.
56. S.W.Tsen, A.H.Paik, C.-F.Hung, et al. Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines. 2007;6(2):227–239.
57. W.-F.Cheng, C.-F.Hung, K.-F.Hsu, et al. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther. 2002;13(4):553–568.
58. P.Berglund, M.Quesada-Rolander, P.Putkonen, et al. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses. 1997;13(17):1487–1495.
59. K.F.Hsu, C.F.Hung, W.F.Cheng, et al. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther. 2001;8(5):376–383.
60. T.W.Kim, C.-F.Hung, J.Juang, et al. Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death. Gene Ther. 2004;11(3):336–342.
61. A.N.Varnavski, P.R.Young, A.A.Khromykh. Stable high-level expression of heterologous genes in vitro and in vivo by noncytopathic DNA-based Kunjin virus replicon vectors. J Virol. 2000;74(9):4394–4403.
62. K.A.Herd, T.Harvey, A.A.Khromykh, et al. Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour. Virology. 2004;319(2):237–248.
63. M.Sebastian, A.Papachristofilou, C.Weiss, et al. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive(R)) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer. 2014;14:748.
64. J.Mackova, L.Kutinova, P.Hainz, et al. Adjuvant effect of dendritic cells transduced with recombinant vaccinia virus expressing HPV16-E7 is inhibited by co-expression of IL12. Int J Oncol. 2004;24(6):1581–1588.
65. T.L.Wang, M.Ling, I.M.Shih, et al. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther. 2000;7(9):726–733.
66. F.Benencia, M.C.Courreges, G.Coukos. Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells. J Transl Med. 2008;6:21.
67. M.Murakami, K.J.Gurski, F.M.Marincola, et al. Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells. Cancer Res. 1999;59(6):1184–1187.
68. S.Peng, T.W.Kim, J.H.Lee, et al. Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. Hum Gene Ther. 2005;16(5):584–593.
69. J.H.Kim, T.H.Kang, K.H.Noh, et al. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death. Immunol Lett. 2009;122(1):58–67.
70. M.Adams, H.Navabi, B.Jasani, et al. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]: poly[C(12)U] (Ampligen R). Vaccine. 2003;21(7–8):787–790.
71. A.D.Santin, S.Bellone, J.J.Roman, et al. Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. Curr Pharm Des. 2005;11(27):3485–3500.
72. Y.-H.Ahn, S.-O.Hong, J.H.Kim, et al. The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-beta receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity. Clin Exp Immunol. 2015;181(1):164–178.
73. R.Mikyskova, M.Indrova, J.Simova, et al. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF. Int J Oncol. 2004;24(1):161–167.
74. E.Y.Chang, C.H.Chen, H.Ji, et al. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Journal International du Cancer [Int J Cancer]. 2000;86(5):725–730.
75. F.R.Vogel. Immunologic adjuvants for modern vaccine formulations. Ann N Y Acad Sci. 1995;754:153–160.
76. L.E.Guimaraes, B.Baker, C.Perricone, et al., Vaccines, adjuvants and autoimmunity. Pharmacol Res. 2015;100:190–209.• A detailed review discussing the mechanism, advantages, and drawbacks of adjuvants.
77. D.T.O’Hagan, N.M.Valiante. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov. 2003;2(9):727–735.
78. W.F.Cheng, C.F.Hung, C.Y.Chai, et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest. 2001;108(5):669–678.
79. B.Yang, A.Yang, S.Peng, et al. Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination. Cell Biosci. 2015;5:35.
80. T.W.Kim, C.-F.Hung, M.Zheng, et al. A DNA vaccine co-expressing antigen and an anti-apoptotic molecule further enhances the antigen-specific CD8+ T-cell immune response. J Biomed Sci. 2004;11(4):493–499.
81. D.O.Villarreal, M.C.Wise, R.J.Siefert, et al. Ubiquitin-like molecule ISG15 acts as an immune adjuvant to enhance antigen-specific CD8 T-cell tumor immunity. Mol Ther J Am Soc Gene Ther. 2015;23:1653–1662.
82. R.Heidenreich, E.Jasny, A.Kowalczyk, et al. A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile. Journal International du Cancer [Int J Cancer]. 2015;137(2):372–384.
83. C.H.Chen, T.L.Wang, C.F.Hung, et al. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine. 2000;18(19):2015–2022.
84. A.P.Wlazlo, H.Deng, W.Giles-Davis, et al. DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins. Cancer Gene Ther. 2004;11(6):457–464.
85. S.Rittich, M.Duskova, J.Mackova, et al. Combined immunization with DNA and transduced tumor cells expressing mouse GM-CSF or IL-2. Oncol Rep. 2005;13(2):311–317.
86. C.-T.Lin, C.-F.Hung, J.Juang, et al. Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles. Mol Ther J Am Soc Gene Ther. 2003;8(4):559–566.
87. J.Mackova, J.Stasikova, L.Kutinova, et al. Prime/boost immunotherapy of HPV16-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara. Cancer Immunol Immunother CII. 2006;55(1):39–46.
88. F.Y.Yue, R.Dummer, R.Geertsen, et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Journal International du Cancer [Int J Cancer]. 1997;71(4):630–637.
89. L.Gorelik, R.A.Flavell. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med. 1118-1122;7(10):2001.
90. C.-M.Chuang, T.Hoory, A.Monie, et al. Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells. Vaccine. 2009;27(5):684–689.
91. A.E.Rice, Y.E.Latchman, J.P.Balint, et al. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression. Cancer Gene Ther. 2015;22:454–462.
92. H.Yu, M.Kortylewski, D.Pardoll. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7(1):41–51.
93. D.H.Munn, A.L.Mellor. IDO and tolerance to tumors. Trends Mol Med. 2004;10(1):15–18.
94. N.Rubinstein, M.Alvarez, N.W.Zwirner, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell. 2004;5(3):241–251.
95. V.Groh, J.Wu, C.Yee, et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419(6908):734–738.
96. R.Kim, M.Emi, K.Tanabe, et al. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006;66(11):5527–5536.
97. K.N.Prasad, B.Kumar, X.-D.Yan, et al. Alpha-tocopheryl succinate, the most effective form of vitamin E for adjuvant cancer treatment: a review. J Am Coll Nutr. 2003;22(2):108–117.
98. T.H.Kang, J.Knoff, W.H.Yeh, et al. Treatment of tumors with vitamin E suppresses myeloid derived suppressor cells and enhances CD8 + T cell-mediated antitumor effects. Plos One. 2014;9(7):e103562.
99. T.Bartkowiak, S.Singh, G.Yang, et al. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc Natl Acad Sci U S A. 2015;112(38):E5290–5299.
100. S.Y.Lee, Z.Huang, T.H.Kang, et al. Histone deacetylase inhibitor AR-42 enhances E7-specific CD8(+) T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination. J Mol Med (Berl). 2013;91(10):1221–1231.
101. R.-S.Soong, L.Song, J.Trieu, et al. Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNgamma. Clin Cancer Res Off J Amer Assoc Cancer Res. 2014;20(21):5456–5467.• This study demonstrated the immune recruitment effect of local adjuvant application.
102. S.-J.Lee, L.Song, M.-C.Yang, et al. Local administration of granulocyte macrophage colony-stimulating factor induces local accumulation of dendritic cells and antigen-specific CD8+ T cells and enhances dendritic cell cross-presentation. Vaccine. 2015;33(13):1549–1555.
103. D.Lu, T.Hoory, A.Monie, et al. Treatment with demethylating agent, 5-aza-2ʹ-deoxycytidine enhances therapeutic HPV DNA vaccine potency. Vaccine. 2009;27(32):4363–4369.
104. T.H.Kang, J.H.Lee, C.K.Song, et al. Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res. 2007;67(2):802–811.
105. S.H.Bae, Y.-J.Park, J.-B.Park, et al. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin Cancer Res Off J Amer Assoc Cancer Res. 2007;13(1):341–349.
106. G.W.Ye, J.-B.Park, Y.-J.Park, et al. Increased sensitivity of radiated murine cervical cancer tumors to E7 subunit vaccine-driven CTL-mediated killing induces synergistic anti-tumor activity. Mol Ther J Am Soc Gene Ther. 2007;15(8):1564–1570.
107. C.-W.Tseng, A.Monie, C.-Y.Wu, et al. Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination. J Mol Med (Berl). 2008;86(8):899–908.
108. C.-W.Tseng, C.Trimble, Q.Zeng, et al. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunol Immunother CII. 2009;58(5):737–748.
109. C.-M.Chuang, A.Monie, A.Wu, et al. Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects. J Biomed Sci. 2009;16:49.
110. D.Patel, S.Shukla, S.Gupta. Apigenin and cancer chemoprevention: progress, potential and promise (review). Int J Oncol. 2007;30(1):233–245.
111. C.W.Tseng, A.Monie, C.Trimble, et al. Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. Vaccine. 2008;26(34):4314–4319.
112. C.-Y.Wu, L.-H.Yang, H.-Y.Yang, et al. Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res Off J Amer Assoc Cancer Res. 2014;20(3):644–657.•• This study suggested that radiotherapy converts the radiated tumor site to favor the generation of immune responses elicited by therapeutic vaccines.
113. S.Peng, S.Lyford-Pike, B.Akpeng, et al. Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunol Immunother CII. 2013;62(1):171–182.
114. S.Peng, J.W.Wang, B.Karanam, et al. Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer. Plos One. 2015;10(1):e116389.
115. S.Y.Lee, T.H.Kang, J.Knoff, et al. Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects. Cancer Immunology, Immunotherapy: CII. 2013;62(7):1175–1185.
116. C.Trimble, C.-T.Lin, C.-F.Hung, et al. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine. 2003;21(25–26):4036–4042.
117. L.A.Babiuk, H.van Drunen Littel-van den, S.L.Babiuk. Immunization of animals: from DNA to the dinner plate. Vet Immunol Immunopathol. 1999;72(1–2):189–202.
118. S.R.Best, S.Peng, C.-M.Juang, et al. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine. 2009;27(40):5450–5459.
119. S.W.Tsen, C.-Y.Wu, A.Meneshian, et al. Femtosecond laser treatment enhances DNA transfection efficiency in vivo. J Biomed Sci. 2009;16:36.
120. B.Klencke, M.Matijevic, R.G.Urban, et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res Off J Amer Assoc Cancer Res. 2002;8(5):1028–1037.
121. L.Jeanbart, M.Ballester, A.de Titta, et al. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes. Cancer Immunol Res. 2014;2(5):436–447.
122. Y.Sun, S.Peng, J.Qiu, et al. Intravaginal HPV DNA vaccination with electroporation induces local CD8+ T-cell immune responses and antitumor effects against cervicovaginal tumors. Gene Ther. 2015;22(7):528–535.•• This study demonstrated that local administration of the therapeutic vaccine lead to more potent local immune responses and antitumor effects.
123. P.C.Maciag, S.Radulovic, J.Rothman. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine. 2009;27(30):3975–3983.
124. K.Kawana, K.Adachi, S.Kojima, et al. Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients. Vaccine. 2014;32(47):6233–6239.
125. J.-L.Brun, V.Dalstein, J.Leveque, et al. Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol. 2011;204(2):169 e161–168.
126. C.M.Corona Gutierrez, A.Tinoco, T.Navarro, et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther. 2004;15(5):421–431.
127. Y.C.A.Albarran, A.De La Garza, B.J.Cruz Quiroz, et al. MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study. Biodrugs Clin Immunotherapeutics Biopharmaceuticals Gene Ther. 2007;21(1):47–59.
128. R.Rosales, M.Lopez-Contreras, C.Rosales, et al. Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine. Hum Gene Ther. 2014;25(12):1035–1049.•• A phase III clinical trial to test the efficacy of therapeutic HPV vaccines in high grade CIN patients.
129. G.G.Kenter, M.J.Welters, A.R.Valentijn, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361(19):1838–1847.
130. P.J.De Vos Van Steenwijk, T.H.Ramwadhdoebe, M.J.Lowik, et al. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol Immunother CII. 2012;61(9):1485–1492.
131. M.I.Van Poelgeest, M.J.Welters, E.M.Van Esch, et al. HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med. 2013;11:88.
132. P.J.de Vos van Steenwijk, M.I.Van Poelgeest, T.H.Ramwadhdoebe, et al. The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study. Cancer Immunol Immunother CII. 2014;63(2):147–160.
133. D.P.Zandberg, S.Rollins, O.Goloubeva, et al. A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). Cancer Immunol Immunother CII. 2015;64(3):367–379.
134. A.de Jong, T.O’Neill, A.Y.Khan, et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine. 2002;20(29–30):3456–3464.
135. S.Daayana, E.Elkord, U.Winters, et al. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer. 2010;102(7):1129–1136.
136. E.J.Davidson, R.L.Faulkner, P.Sehr, et al. Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine. 2004;22(21–22):2722–2729.
137. L.J.Smyth, M.I.Van Poelgeest, E.J.Davidson, et al. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res an Off J Amer Assoc Cancer Res. 2004;10(9):2954–2961.
138. L.Maldonado, J.E.Teague, M.P.Morrow, et al. Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci Transl Med. 2014;6(221):221ra213.
139. T.J.Kim, H.T.Jin, S.Y.Hur, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun. 2014;5:5317.
140. M.L.Bagarazzi, J.Yan, M.P.Morrow, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med. 2012;4(155):155ra138.
141. C.L.Trimble, M.P.Morrow, K.A.Kraynyak, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386(10008):2078–2088.
142. A.D.Santin, S.Bellone, M.Palmieri, et al. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol. 2008;82(4):1968–1979.
143. P.Ramanathan, S.Ganeshrajah, R.K.Raghanvan, et al. Development and clinical evaluation of dendritic cell vaccines for HPV related cervical cancer–a feasibility study. Asian Pacific J Cancer Prev APJCP. 2014;15(14):5909–5916.
144. G.R.Gunn, A.Zubair, C.Peters, et al. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol. 2001;167(11):6471–6479.
145. C.Rosales, V.V.Graham, G.A.Rosas, et al. A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity. Cancer Immunol Immunother CII. 2000;49(7):347–360.
146. S.Zwaveling, S.C.Ferreira Mota, J.Nouta, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol. 2002;169(1):350–358.
147. S.H.van der Burg, K.M.Kwappenberg, T.O’Neill, et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine. 2001;19(27):3652–3660.
148. J.Yan, K.Harris, A.S.Khan, et al. Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. Vaccine. 2008;26(40):5210–5215.
149. J.Yan, D.K.Reichenbach, N.Corbitt, et al. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine. 2009;27(3):431–440.